Abstract:Abstract The effects of tumor-associated neutrophils (TANs) on glioblastoma biology remain poorly understood. Flow cytometric analysis of 5 newly diagnosed glioblastoma fresh tissue specimens surprisingly revealed a high fraction (21.0-34.1%) of TANs expressed MHCII, a marker of antigen-presenting cells not classically associated with neutrophils and not expressed in matched peripheral blood (PBNs). Transcriptomic profiling confirmed that patient TANs upregulated expression of MHCII subunits (HLA-DR), chaperones (HLA-DM), and costimulatory ligands (CD86/83). Ex vivo cocultures further demonstrated that TANs activated patient-matched naïve T cells in an MHCII-dependent manner, while PBNs did not (CD25 MFI fold-change: 1.1 vs 3.2, p< 0.001). The antitumoral relevance of this property was confirmed in a syngeneic mouse glioma model, wherein αLy6G-mediated neutrophil depletion in T-cell-competent mice (Balb/c, n= 13) yielded endpoint tumors that had reduced CD8+ T cell infiltration (p= 0.0024) and were 2.4-fold larger by BLI (p= 0.0383) than controls, but had no bearing on tumor burden in T-cell-deficient (athymic) mice. Given the absence of MHCII+ neutrophils in circulation, we interrogated the inducibility of this phenotype by tumor-conditioned media in murine marrow/blood, finding that only immature Ly6Glow bone marrow neutrophils had sufficient plasticity to express MHCII and process foreign antigen as measured by DQ-ovalbumin uptake/proteolysis. Because of the non-inducibility of PBNs, we investigated the hypothesis that MHCII+ TANs were recruited to the glioblastoma microenvironment from adjacent skull bone marrow by labeling this space with CFMDA in tumor-implanted mice; at 72h, skull marrow-derived neutrophils contributed disproportionately to MHCII+ TANs compared to all TANs (41.7% vs 9.3%). As confirmation, in the first-ever scRNA-seq of human TANs, we demonstrated via pseudotime analysis that MHCII+ neutrophils represent a developmental lineage seen in TANs but not matched PBNs. Given the immunostimulatory effects of this population, mechanisms to promote neutrophil egress and tumor infiltration from the skull marrow may have therapeutic value.

Mononuclear myeloid cells can shape neutrophils in brain tumors

The local microenvironment drives activation of neutrophils in human brain tumors

[Neutrophils in the tumor microenvironment-foes or friends?]

Tumor-specific Neutrophils Originating from Meninges Promote Glioblastoma

Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma

Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies

517 Glioblastoma Induces the Recruitment of Anti-Tumoral Immunostimulatory Neutrophils from Skull Bone Marrow

Neutrophils in glioma microenvironment: from immune function to immunotherapy

Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy

Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model

Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal

Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment

Naive primary neutrophils play a dual role in the tumor microenvironment

Glioblastoma induces the recruitment and differentiation of hybrid neutrophils from skull bone marrow

Roles of Neutrophils in Glioma and Brain Metastases

Neutrophils in cancer: dual roles through intercellular interactions

Neutrophils in Cancer immunotherapy: friends or foes?

TMIC-59. GLIOBLASTOMA INDUCES THE DIFFERENTIATION AND RECRUITMENT OF NON-CANONICAL ANTI-TUMORAL NEUTROPHILS FROM SKULL BONE MARROW

The tumor niche can reprogram long-lived protumorigenic neutrophils

Targeting myeloid cells in the tumor sustaining microenvironment

Neutrophil extracellular traps promote tumor chemoresistance to anthracyclines